Catechol-O-methyltransferase, dopamine, and sleep-wake regulation

Sleep Medicine Reviews

Volumn 22, Issue , 2015, Pages 47-53

  Dauvilliers, Yves ^a   Tafti, Mehdi ^b,c   Landolt, Hans Peter ^d  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Catechol O methyltransferase; Catecholamines; Dopamine; Genetics; Narcolepsy; Performance; Pharmacogenetic; Prefrontal; Vigilance

Indexed keywords

AMPHETAMINE; CATECHOL METHYLTRANSFERASE; DOPAMINE; ENTACAPONE; MODAFINIL; TOLCAPONE; COMT PROTEIN, HUMAN;

CATECHOLAMINE RELEASE; COMT GENE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; EPWORTH SLEEPINESS SCALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MOLECULAR CLONING; NARCOLEPSY; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PHARMACOGENETICS; PREFRONTAL CORTEX; PROTEIN DEGRADATION; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; VENTRAL TEGMENTUM; AROUSAL; ENZYMOLOGY; FRONTAL LOBE; GENETICS; PHYSIOLOGY; SLEEP; SLEEP WAKE DISORDERS;

AROUSAL; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; FRONTAL LOBE; HUMANS; NARCOLEPSY; SLEEP; SLEEP WAKE DISORDERS;

EID: 84937852522     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2014.10.006     Document Type: Review

References (55)

1. Dauvilliers Y., Maret S., Tafti M. Genetics of normal and pathological sleep in humans. Sleep Med Rev 2005, 9:91-100.
2. Landolt H.P. Genotype-dependent differences in sleep, vigilance and response to stimulants. Curr Pharm Des 2008, 14:3396-3407.
3. De Gennaro L., Marzano C., Fratello F., Moroni F., Pellicciari M.C., Ferlazzo F., et al. The electroencephalographic fingerprint of sleep is genetically determined: a twin study. Ann Neurol 2008, 64:455-460.
4. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Nat Acad Sci 1998, 95:9991-9996.
5. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004, 75:807-821.
6. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol O methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
7. Spielman R.S., Weinshilboum R.M. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981, 10:279-290.
8. Palmatier M.A., Kang A.M., Kidd K.K. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiat 1999, 46:557-567.
9. Weinshilboum R.M., Otterness D.M., Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev Pharmacol Toxicol 1999, 39:19-52.
10. Lee S.G., Joo Y., Kim B., Chung S., Kim H.L., Lee I., et al. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum Genet 2005, 116:319-328.
11. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
12. Monti J.M., Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007, 11:113-133.
13. Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cereb Cortex 2007, 17(Suppl. 1):i161-i170.
14. Lewis D.A., Sesack S.R., Levey A.I., Rosenberg D.R. Dopamine axons in primate prefrontal cortex: specificity of distribution, synaptic targets, and development. Adv Pharmacol 1998, 42:703-706.
15. Karoum F., Chrapusta S.J., Egan M.F. 3-Methoxytryramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994, 63:972-979.
16. Moore R.Y., Bloom F.E. Central catecholamine neuron system: anatomy and physiology of the dopamine systems. Annual review of neuroscience 1978, vol. 1:129-169. Annual Reviews Inc, Palo Alto.
17. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984, 4:2877-2890.
18. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
19. Holst S.C., Bersagliere A., Bachmann V., Berger W., Achermann P., Landolt H.P. Dopaminergic role in regulating neurophysiological markers of sleep homeostasis in humans. J Neurosci 2014, 34:566-573.
20. Ongini E., Caporali M.G. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behavior in the rat. Neuropharmacology 1987, 26:355-360.
21. Monti J.M., Hawkins M., Jantos H., D'Angelo L., Fernández M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology 1988, 95:395-400.
22. Trampus M., Ferri N., Adami M., Ongini E. The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol 1993, 235:83-87.
23. Jones B.E., Bobillier P., Pin C., Jouvet M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res 1973, 58:157-177.
24. Rye D.B. Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med 2004, 5:317-328.
25. Shansky R.M., Glavis-Bloom C., Lerman D., McRae P., Benson C., Miller K., et al. Estrogen mediates sex differences in stress-induced-prefrontal cortex dysfunction. Mol Psychiatry 2004, 9:531-538.
26. Thierry A.M., Tassin J.P., Blanc G., Glowinski J. Selective activation of the mesocortical DA system by stress. Nature 1976, 263:242-244.
27. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005, 8:594-596.
28. Bruder G.E., Keilp J.G., Xu H., Shikhman M., Schori E., Gorman J.M., et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiat 2005, 58:901-907.
29. Bodenmann S., Rusterholz T., Dürr R., Stoll C., Bachmann V., Geissler E., et al. The functional Val158Met polymorphism of COMT predicts inter-individual differences in brain alpha oscillations in young men. J Neurosci 2009, 29:10855-10862.
30. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Rev 1999, 29:169-195.
31. Goel N., Banks S., Lin L., Mignot E., Dinges D.F. Catechol-O-methyltransferase Val158Met polymorphism associates with individual differences in sleep physiologic responses to chronic sleep loss. PLoS One 2011, 6:e29283.
32. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006, 60:141-151.
33. Valomon A., Holst S.C., Bachmann V., Viola A., Schmidt C., Zürcher J., et al. Genetic polymorphisms of DAT1 and COMT differently affect actigraphy-derived sleep-wake cylces in humans. Chronobiol Int 2014, 31:705-714.
34. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
35. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
36. Bourgin P., Huitrón-Résendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000, 15(20):7760-7765.
37. Burgess C.R., Tse G., Gillis L., Peever J.H. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010, 33:1295-1304.
38. Dauvilliers Y., Neidhart E., Lecendreux M., Billiard M., Tafti M. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367-372.
39. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78.
40. Hor H., Kutalik Z., Dauvilliers Y., Valsesia A., Lammers G.J., Donjacour C.E., et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010, 42:786-789.
41. Kornum B.R., Kawashima M., Faraco J., Lin L., Rico T.J., Hesselson S., et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011, 43:66-71.
42. Faraco J., Lin L., Kornum B.R., Kenny E.E., Trynka G., Einen M., et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013, 9:e1003270.
43. Luca G., Haba-Rubio J., Dauvilliers Y., Lammers G.J., Overeem S., Donjacour C.E., et al. European Narcolepsy Network. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res 2013, 22:482-495.
44. Frauscher B., Högl B., Maret S., Wolf E., Brandauer E., Wenning G.K., et al. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. Sleep 2004, 27:733-736.
45. Rissling I., Frauscher B., Kronenberg F., Tafti M., Stiasny-Kolster K., Robyr A.C., et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep 2006, 29:108-111.
46. Mylius V., Möller J.C., Strauch K., Oertel W.H., Stiasny-Kolster K. No significance of the COMT val158met polymorphism in restless legs syndrome. Neurosci Lett 2010, 473:151-154.
47. Tafti M., Dauvilliers Y. Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics 2003, 4:23-33.
48. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 18(301):1148-1154.
49. Dauvilliers Y., Neidhart E., Billiard M., Tafti M. Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J 2002, 2:65-68.
50. Bodenmann S., Landolt H.P. Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT. Sleep 2010, 33:1027-1035.
51. Bodenmann S., Xu S., Luhmann U.F., Arand M., Berger W., Jung H.H., et al. Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clin Pharmacol Ther 2009, 85:296-304.
52. Pérez-Mañá C., Castells X., Torrens M., Capellà D., Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 2013, 9:CD009695.
53. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., et al. Catechol 0-methyltransferase val158-to-met genotype and individual variation in the brain response to amphetamine. Proc Nat Acad Sci 2003, 100:6186-6191.
54. Levy F. Stimulant side effects and inverted-U: implications for ADHD guidelines. Aust N. Z J Psychiatry 2013, 47:217-221.
55. Nackley A.G., Shabalina S.A., Lambert J.E., Conrad M.S., Gibson D.G., Spiridonov A.N., et al. Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs. PLoS One 2009, 4:e5237.